J. Goldman & CO LP Immatics N.V. Call Options Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
Call Options
3 transactions
Others Institutions Holding IMTX
# of Institutions
93Shares Held
92.5MCall Options Held
313KPut Options Held
377K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.6MShares$48.8 Million0.05% of portfolio
-
Wellington Management Group LLP Boston, MA10.4MShares$47.9 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$43.2 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$33.5 Million0.57% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$30.1 Million0.76% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $351M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...